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TECHNOLOGY FEATURE

OPEN

Large-scale computational drug repositioning to ﬁnd
treatments for rare diseases
Rajiv Gandhi Govindaraj1, Misagh Naderi

1

, Manali Singha1, Jeffrey Lemoine1,2 and Michal Brylinski

1,3

Rare, or orphan, diseases are conditions afﬂicting a small subset of people in a population. Although these disorders collectively
pose signiﬁcant health care problems, drug companies require government incentives to develop drugs for rare diseases due to
extremely limited individual markets. Computer-aided drug repositioning, i.e., ﬁnding new indications for existing drugs, is a
cheaper and faster alternative to traditional drug discovery offering a promising venue for orphan drug research. Structure-based
matching of drug-binding pockets is among the most promising computational techniques to inform drug repositioning. In order
to ﬁnd new targets for known drugs ultimately leading to drug repositioning, we recently developed eMatchSite, a new computer
program to compare drug-binding sites. In this study, eMatchSite is combined with virtual screening to systematically explore
opportunities to reposition known drugs to proteins associated with rare diseases. The effectiveness of this integrated approach is
demonstrated for a kinase inhibitor, which is a conﬁrmed candidate for repositioning to synapsin Ia. The resulting dataset
comprises 31,142 putative drug-target complexes linked to 980 orphan diseases. The modeling accuracy is evaluated against the
structural data recently released for tyrosine-protein kinase HCK. To illustrate how potential therapeutics for rare diseases can be
identiﬁed, we discuss a possibility to repurpose a steroidal aromatase inhibitor to treat Niemann-Pick disease type C. Overall, the
exhaustive exploration of the drug repositioning space exposes new opportunities to combat orphan diseases with existing drugs.
DrugBank/Orphanet repositioning data are freely available to research community at https://osf.io/qdjup/.
npj Systems Biology and Applications (2018)4:13; doi:10.1038/s41540-018-0050-7

INTRODUCTION
Repositioning drugs to treat conditions for which they were not
originally intended is an emerging strategy offering a faster and
cheaper route to develop new treatments compared to traditional
drug discovery.1 Since repurposed molecules not only have
optimized pharmacokinetics, pharmacodynamics, and toxicity
proﬁles, but are also already approved by the U.S. Food and Drug
Administration (FDA), this approach speeds up the evaluation of
drug candidates in clinical trials at the reduced risk of failure. Drug
repositioning is expected to play a major role in the development
of treatments for rare, or orphan, diseases deﬁned as those
disorders afﬂicting <200,000 patients in the United States. Even
though rare diseases collectively affect more than 350 million
people worldwide (https://globalgenes.org/rare-diseases-factsstatistics/), developing new therapeutics for their small individual
markets is not proﬁtable enough to warrant commercial interest.2
On that account, many countries passed orphan drug legislation,
such as the Orphan Drug Act of 1983 in the U.S., in order to
provide ﬁnancial inducements in terms of the market exclusivity
and reduced development costs. Legislators work on the Orphan
Product Extensions Now Accelerating Cures and Treatments
(OPEN) Act to extend the market exclusivity for repurposing
already approved drugs to treat rare diseases,3 signifying the
importance of drug repositioning to orphan disease research.
It is noteworthy that most repurposed drugs are the result of
serendipitous observations made either in the lab or during
clinical tests. Sildenaﬁl is perhaps the most recognized example of

a repositioned compound. Originally developed to treat hypertension and angina pectoris in the 1980s, it was later repurposed to
erectile dysfunction and pulmonary arterial hypertension.4 Other
examples are amantadine and memantine. The former was
introduced in the 1960s as a prophylactic agent in respiratory
infections.5 A few years later, a patient with Parkinson’s disease
experienced a dramatic improvement in her symptoms during the
daily administration of amantadine for inﬂuenza prophylaxis.6 This
anecdotal observation stimulated research on using amantadine
and other members of the aminoadamantane class of molecules
to treat neurological diseases. Indeed, amantadine is presently
approved by the FDA as both an antiviral and an antiparkinsonian
drug. Structurally similar to amantadine, memantine was also
synthesized in the 1960s as a putative hypoglycemic agent,
though it was found to be devoid of such activity. It was later
discovered that memantine is an uncompetitive antagonist of
glutamatergic N-methyl-D-aspartate (NMDA) receptors7 and currently, memantine is used to treat moderate to severe Alzheimertype dementia.8
A clear necessity for rational approaches to ﬁnd alternative
indications for existing therapeutics has stimulated the development of computational methods for drug repositioning.9 Many
currently available algorithms exploit the fact that proteins with
similar pockets tend to have similar functions and recognize
similar molecules.10 For instance, the sequence-order independent
proﬁle-proﬁle alignment (SOIPPA) program employs Delaunay
tessellation of Cα atoms and geometric potentials to compare
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binding pockets.11 Further, SiteAlign measures distances between
druggable pockets with cavity ﬁngerprints constructed by
projecting eight topological and physicochemical properties onto
a multidimensional, discretized space.12 Both SOIPPA and
SiteAlign have been used in drug repurposing, for example,
SOIPPA helped reveal new targets for entacapone and tolcapone,13 whereas SiteAlign detected the cross-reaction of protein
kinase inhibitors with a protein regulating neurotransmitter
release in the synapse.14
Notwithstanding the success of existing methods to recognize
similar pockets, many of these algorithms perform well only
against the experimental structures of proteins complexed with
small molecules. Utilizing datasets of target structures with
predicted binding sites poses a formidable challenge for pocket
matching programs because of inevitable inaccuracies in the
annotation of binding residues. To alleviate this issue, we recently
developed eMatchSite, which offers a high tolerance to residue
misannotations and, to some extent, structure imperfections in
ligand-binding regions.15,16 In this communication, we combine
eMatchSite and structure-based virtual screening (VS) with
AutoDock Vina17 in order to enhance the accuracy of binding
site matching. Subsequently, we demonstrate the effectiveness of
eMatchSite/VS for a kinase inhibitor, which is a conﬁrmed
candidate for repositioning to synapsin Ia. Next, this methodology
is employed to explore new opportunities to combat orphan
conditions through a large-scale repositioning of existing drugs to
proteins linked to rare diseases.18 The results are discussed with
respect to the structural data recently released in the Protein Data
Bank (PDB)19 for tyrosine-protein kinase HCK, as well as a
possibility to repurpose a steroidal aromatase inhibitor to treat
Niemann-Pick disease type C. Overall, the protocol combining
protein structure modeling, binding site prediction and matching,
and structure-based virtual screening holds a signiﬁcant promise
to systematically explore the drug repositioning space at the
systems level.
RESULTS AND DISCUSSION
Integrating binding site matching with virtual screening
Although the primary application of VS is to identify potentially
bioactive molecules, it can also be used to indirectly measure the
similarity between binding sites.20 Speciﬁcally, VS is conducted
against a pair of target pockets and then a statistical dependence
between the ranking of library compounds is evaluated by
Spearman’s ρ rank correlation coefﬁcient. A high positive Spearman’s ρ indicates that two binding sites are chemically similar, i.e.,
tend to bind similar compounds (Supplementary Text S1). Here,
we employ structure-based VS with Vina to increase the accuracy
of eMatchSite detecting similar binding sites. Since many proteins
associated with rare diseases are yet to be experimentally
annotated, repositioning drugs to orphan proteins is generally
dependent on the accuracy of pocket matching conducted
against computationally predicted binding sites. On that account,
we run both eMatchSite and Vina on pockets predicted by
eFindSite for ligand-bound and unbound structures in the Huang
dataset.21
The performance is assessed in Fig. 1 with the BoltzmannEnhanced Discrimination of Receiver Operating Characteristic
(BEDROC, Supplementary Text S2) devised to statistically evaluate
the early recognition capabilities of binary classiﬁers.22 Using the
bound structures, the median BEDROC score for eMatchSite alone
is 0.66, which increases to 0.77 when it is combined with VS. As
expected, the performance for unbound structures is somewhat
lower compared to bound structures, however, including VS
brings about similar improvements. The median BEDROC for
unbound structures increases from 0.60 for eMatchSite to 0.71 for
eMatchSite/VS. For comparison, the performance of a random
npj Systems Biology and Applications (2018) 13

Fig. 1 Performance assessment for the recognition of pockets
binding similar ligands. The performance of eMatchSite alone and
including virtual screening, labeled as eMatchSite/VS, is evaluated
with BEDROC against the Huang dataset and compared to that of a
random classiﬁer. The Huang dataset contains ligand-bound and
unbound structures. Boxes end at the quartiles Q1 and Q3, the
horizontal line in a box is the median, and whiskers point at the
farthest points that are within 3/2 times the interquartile range

classiﬁer is notably lower with the median BEDROC values of 0.18
for bound and 0.21 for unbound structures. Overall, combining
pocket matching with methodologically orthogonal structurebased VS is an effective strategy to increase the accuracy of
detecting pockets binding similar ligands regardless of the
conformational state of target proteins.
Example of a validated candidate for repositioning
The capability of eMatchSite to correctly recognize similar ligandbinding sites in primary and off-targets is demonstrated for a
conﬁrmed candidate for repositioning. Here, we conduct pocket
matching followed by VS against weakly homologous protein
models constructed by eThread with binding sites predicted by
eFindSite. This procedure is essentially the same as that employed
to reposition existing drugs to proteins linked to rare diseases.18
The example shown in Fig. 2 is the cross-reaction of staurosporine,
a pan-kinase inhibitor,23 with synapsin Ia, an ATP-binding protein
regulating neurotransmitter release in the synapse.14 A weakly
homologous model of the primary target for staurosporine, the
human proto-oncogene serine/threonine-protein kinase Pim-1,
was built based on the structure of the murine AMP-activated
protein kinase (PDB-ID: 5ufu, chain A, 31.3% sequence identity to
Pim-1).24 This model has a Template Modeling (TM)-score25 of 0.86
and a Cα-root-mean-square deviation (RMSD)26 of 5.47 Å against
the crystal structure of Pim-1 (PDB-ID: 1yhs, chain A),27 with a
Matthews correlation coefﬁcient (MCC)28 between predicted and
staurosporine-binding residues of 0.67. The TM-score and CαRMSD are described in the Supplementary Text S3. The model of
synapsin Ia constructed based on a remote template α-aminoadipate-LysW ligase LysX (PDB-ID: 3vpd, chain A, 22.8% sequence
identity to synapsin Ia)29 has a TM-score of 0.67 and a Cα-RMSD of
9.03 Å against the crystal structure of synapsin Ia (PDB-ID: 1aux,
chain A).30
Although Pim-1 and synapsin Ia have globally different
sequences (a sequence identity of 15.5%) and structures (a TMscore of 0.32), eMatchSite predicted that pockets in both models
are in fact highly similar with an eMS-score (Supplementary Text
S4) of 0.97. Figure 2a presents the local superposition of binding
sites in Pim-1 (purple ribbons and spheres) and synapsin Ia (gold
ribbons and spheres) models resulting in a Cα-RMSD of 2.47 Å
over 13 aligned residues. In addition to staurosporine repositioned
Published in partnership with the Systems Biology Institute
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Fig. 2 Example of a successful drug repositioning with eMatchSite. Staurosporine is repositioned from serine/threonine-protein kinase Pim-1
to synapsin Ia. a The local superposition of binding pockets according to the eMatchSite alignment. The computer-generated model of the
primary target, Pim-1, is represented by transparent purple ribbons, whereas the model of the off-target, synapsin Ia, is represented by solid
gold ribbons. Binding residues predicted by eFindSite are shown as spheres. The repositioned drug is presented as solid sticks colored by
atom type (gold–carbon, red–oxygen, blue–nitrogen). ATP bound to synapsin Ia is shown as transparent sticks colored by atom type
(teal–carbon, red–oxygen, blue–nitrogen, yellow–sulfur, peach–phosphorus). b A scatter plot for the correlation of ranks from virtual screening
conducted by Vina. Each dot represents one library compound, whose ranks against the primary target and off-target are displayed on x and y
axes, respectively. A dashed black line is the diagonal corresponding to a perfect correlation

to synapsin Ia (solid gold sticks), Fig. 2a includes an ATP-γS
molecule bound to the active site of synapsin Ia (transparent teal
sticks). Encouragingly, staurosporine transferred according to the
local Pim-1→synapsin Ia alignment adopts an orientation closely
resembling those of typical ATP-competitive inhibitors bound to
protein kinases.31 Further, Spearman’s ρ calculated for ranks
assigned by Vina is as high as 0.86 (Fig. 2b) strongly indicating that
these pockets are in fact chemically similar. Indeed, competition
experiments of staurosporine against ATP-γS conﬁrmed its
nanomolar binding to synapsin Ia14 corroborating the model
constructed by eMatchSite.
Repositioning of DrugBank compounds to Orphanet proteins
The repositioning procedure was developed in our previous
study18 and it is summarized in Fig. 3. Full-chain structures of
proteins from DrugBank32 and Orphanet (Fig. 3a) are modeled
with eThread33 (Fig. 3b) followed by the annotation of ligandbinding sites with eFindSite34 (Fig. 3c). Next, drug-target
complexes are constructed for DrugBank proteins with a twostep similarity-based docking procedure employing Fr-TM-align35
and KCOMBU36 (Fig. 3d). This protocol generates drug-bound
structures for DrugBank and unbound structures for Orphanet
proteins (Fig. 3e). Subsequently, all DrugBank pockets are
compared against all Orphanet pockets with eMatchSite15,16 and
drugs are transferred from DrugBank to Orphanet proteins for
signiﬁcant matches (Fig. 3f). Finally, Orphanet drug-target complexes are reﬁned with Modeller37 (Fig. 3g) and subjected to
quality assessment with Distance-scaled Finite Ideal-gas REference
(DFIRE)38 and VS17 (Fig. 3h).
All-against-all pockets matching conducted with eMatchSite for
DrugBank and Orphanet proteins produced 320,856 binding site
alignments, 5.6% of which yield a statistically signiﬁcant eMSscore. It is noteworthy that the average TM-score between
matched DrugBank and Orphanet targets is as low as 0.27 ± 0.10
indicating that in the majority of cases, existing drugs are
repositioned from proteins having globally unrelated structures.
Based on 18,145 conﬁdent local alignments reported by
eMatchSite, 31,142 unique putative complexes between DrugBank
compounds and Orphanet proteins have been modeled. An
analysis of the DrugBank→Orphanet repositioning data reveals
that 381 existing drugs could be repurposed to target as many as
Published in partnership with the Systems Biology Institute

Fig. 3 Flowchart of the drug repositioning procedure devised in this
study. For protein sequences from DrugBank and Orphanet (a),
template-based structure modeling is conducted with eThread to
construct 3D models (b). Protein models are subsequently annotated by eFindSite with drug-binding sites (c). A similarity-based
ligand docking is performed for DrugBank drug-protein pairs, i.e., a
globally similar template is aligned onto the target structure with FrTM-align and then the drug is aligned onto the template-bound
ligand with KCOMBU (d). The modeling procedure produces drugbound structures for DrugBank and unbound structures for
Orphanet proteins (e). Next, all-against-all matching of drugbinding pockets in DrugBank and Orphanet proteins is conducted
with eMatchSite (f). The DrugBank compound is transferred to the
Orphanet model when the similarity of binding pockets is
sufﬁciently high and the resulting complex is reﬁned (g). Finally,
the quality of ﬁnal Orphanet complex models is assessed with DFIRE
and virtual screening (h)
npj Systems Biology and Applications (2018) 13
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Fig. 4 Multiple drugs repositioned through a single pocket alignment. Schematic of (a) a single DrugBank target binding two drugs (teal and
yellow), (b) an Orphanet target (green), and (c) two modeled complexes of DrugBank drugs and an Orphanet protein (teal-green and yellowgreen). d A real example of tolcapone (teal) and entacapone (yellow) repositioned to guanine nucleotide-binding protein subunit alpha-11
(green) based on its local alignment with catechol O-methyltransferase. Non-carbon ligand atoms in panel (d) are colored by atom type
(blue–nitrogen, red–oxygen)

761 Orphanet proteins. These proteins link to 980 orphan diseases
representing 32 classes including (ten the most common classes)
923 genetic, 428 neurological, 377 inborn errors of metabolism,
266 developmental anomalies during embryogenesis, 170 eye,
117 skin, 102 bone, 93 neoplastic, 92 endocrine, and 85
hematological disorders.
Repositioning multiple drugs through a single alignment. Drug
repositioning conducted in this study includes two kinds of special
cases. Figure 4 illustrates the ﬁrst situation, in which complexes
between multiple drugs (Fig. 4a) and an Orphanet target (Fig. 4b)
are modeled based on a single pocket alignment. Employing this
approach generates a series of structure models of drugs
transferred from a DrugBank target to the binding site of an
Orphanet protein (Fig. 4c). For instance, catechol Omethyltransferase (COMT) produces a signiﬁcant local alignment
with guanine nucleotide-binding protein subunit alpha-11
(GNA11), associated with a rare disease, autosomal dominant
hypocalcemia (ADH) or hypoparathyroidism39 (ORPHA:428,
GARD:2877). This condition is characterized by low levels of
calcium in the blood and an imbalance of other molecules, such as
phosphate and magnesium, leading to a variety of symptoms,
although about half of affected individuals have no associated
health problems.40 ADH is primarily caused by mutations of a
gene encoding the calcium-sensing receptor, however, activating
mutations in GNA11 have also been reported.41,42 A binding site
predicted in GNA11 by eFindSite aligns well to a pocket binding
tolcapone and entacapone in COMT with an eMS-score of 0.97 and
a Cα-RMSD of 4.5 Å calculated over 14 aligned binding residues.
Based on this single alignment, tolcapone and entacapone, COMT
inhibitors used as adjuncts to levodopa/carbidopa medication in
the treatment of Parkinson’s disease,43,44 could be repositioned to
GNA11. Figure 4d shows the putative binding poses of both
compounds in the binding pocket of GNA11 modeled based on
the local COMT→GNA11 alignment reported by eMatchSite.
Interaction energies with GNA11 reported by DFIRE for tolcapone
and entacapone are −355.7 and −311.7, respectively. For
comparison, the interaction energies with COMT are −283.7 for
tolcapone and −310.9 for entacapone. Overall, these results
indicate that both molecules may favorably bind to GNA11
producing stable, low-energy assemblies.
Construction of multiple models of a single complex. The second
special case is the modeling of a single complex based on multiple
pocket alignments. More than one structure model of a drug
repositioned to the Orphanet protein can be constructed if this
npj Systems Biology and Applications (2018) 13

drug has multiple targets in DrugBank producing signiﬁcant
pocket alignments with the Orphanet protein. This procedure is
illustrated in Fig. 5. Figure 5a shows three DrugBank targets
binding the same compound, colored in blue, orange and yellow.
Assuming that pockets for this drug in all three proteins align to a
binding site in an Orphanet target colored in green (Fig. 5b), three
independent structure models can be constructed (Fig. 5c). An
example is ponatinib, a novel inhibitor of Bcr-Abl tyrosine kinase
developed to treat chronic myeloid leukemia and Philadelphia
chromosome-positive acute lymphoblastic leukemia.45 Ponatinib
is a multi-targeted compound, which in addition to its primary
target, Abelson tyrosine-protein kinase 1, binds to 14 other
macromolecules according to DrugBank.32 Binding sites of three
of these proteins, Lck/Yes-related novel protein tyrosine kinase
(LYN), lymphocyte cell-speciﬁc protein-tyrosine kinase (LSK), and
proto-oncogene tyrosine-protein kinase Src (SRC), produce signiﬁcant local alignments with a drug-binding pocket predicted in
Ras-related protein Rab-23 (RAB23). The corresponding eMS-score/
Cα-RMSD values reported by eMatchSite for these alignments are
0.97/3.8, 0.98/3.7, and 0.98/3.8 Å, respectively. According to
Orphanet, RAB23 is associated with Carpenter syndrome46,47
(ORPHA:65759, GARD:6003), a very rare disease with approximately 40 cases described in the literature.48 The repositioning of
ponatinib to RAB23 can, therefore, be carried out through kinases
LSK, LYN, and SRC, resulting in three independent models of a
ponatinib-RAB23 complex structure. Figure 5d shows that the
binding poses of ponatinib in the RAB23 pocket are very similar
across these models. The heavy-atom RMSD between ponatinib
molecules is 2.1 Å for LSK- and LYN-based models, 0.7 Å for LSKbased and SRC-based models, and 2.3 Å for LYN-based and SRCbased models, with similar drug-protein interactions present in all
models (Supplementary Fig. S1). The interaction energy between
ponatinib and RAB23 reported by DFIRE for LSK-, LYN-, and SRCbased models are −829.7, −727.7, and −723.6, respectively. These
values are even lower than those calculated for the parent
complexes of ponatinib and LSK (−587.9), LYN (−571.9), and SRC
(−586.9) suggesting that ponatinib may form favorable interactions with the binding residues of RAB23.
Multiple structure models of the same complex of a drug
repositioned to the Orphanet target can be used to estimate the
conﬁdence of the large-scale modeling reported in this study.
Speciﬁcally, employing different DrugBank proteins to transfer
the same drug to the Orphanet target should, in principle,
produce similar complex models. To test this assumption, we
selected 4878 drugs repositioned to Orphan targets by
matching binding sites of multiple DrugBank proteins.
Published in partnership with the Systems Biology Institute
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Fig. 5 Multiple models of a single drug-target complex constructed based on multiple pocket alignments. Schematic of (a) three DrugBank
targets binding the same drug (teal, orange, and yellow), (b) an Orphanet target (green), and (c) three poses of a DrugBank drug within the
binding site of an Orphanet protein (teal/orange/yellow-green) modeled from different pocket alignments. (d) A real example of ponatinib
repositioned to Ras-related protein Rab-23 (green) based on its local alignment with Lck/Yes-related novel protein tyrosine kinase (ponatinib is
teal), lymphocyte cell-speciﬁc protein-tyrosine kinase (ponatinib is orange), and proto-oncogene tyrosine-protein kinase Src (ponatinib is
yellow). Non-carbon ligand atoms in panel (d) are colored by atom type (blue–nitrogen, red–oxygen)

Supplementary Fig. S2 shows that up to 20 different models can
be constructed for some drugs, however, two and three models
are generated for the majority of cases (52.4 and 21.9%,
respectively). Next, we identiﬁed the most typical binding pose
of each drug in the pocket of an Orphanet protein by calculating
a ligand heavy-atom RMSD against all other models of the same
drug-target complex. The distribution of these RMSD values
across 4878 DrugBank drugs repositioned to Orphanet targets is
shown as inset in Supplementary Fig. S2. Encouragingly, the
RMSD for most compounds is relatively low with a median value
of 3.6 Å. One should keep in mind that these complex structures
are constructed from the computer-generated models of target
proteins with computationally predicted ligand-binding sites,
and drug molecules are transferred according to fully sequence
order-independent pocket alignments.
Binding afﬁnity prediction for repositioned drugs
We also evaluate the binding afﬁnity of drugs repositioned to
Orphanet proteins in comparison with their complexes with
primary targets from DrugBank. Figure 6 shows the relation
between interaction energies estimated by DFIRE for DrugBank
and Orphanet complexes. The DFIRE statistical potential is
described in the Supplementary Text S5. Because a single drugtarget complex from DrugBank can be used to reposition the
bound drug molecule to multiple Orphanet proteins, mean scores
and the corresponding standard errors of the mean are plotted on
the y-axis. Encouragingly, DFIRE energies calculated for DrugBank
and Orphanet complexes involving the same drug are highly
correlated with a Pearson correlation coefﬁcient of 0.86. This
analysis indicates that the interaction strength of drug molecules
repositioned to Orphanet proteins is generally comparable to that
calculated for their complexes with primary targets. Therefore,
those pairs of DrugBank and Orphanet proteins producing
statistically signiﬁcant pocket alignments also share similarities
with respect to ligand binding as independently evaluated with
knowledge-based statistical potentials.
Validation against a recently determined X-ray structure
Repositioning prediction by eMatchSite is further validated against
a complex structure released in the PDB several months after the
modeling was completed. Figure 7 shows ibrutinib (DrugBank-ID:
DB09053), an anti-cancer drug primarily targeting B-cell malignancies,49 predicted to bind to proto-oncogene, Src family
tyrosine kinase Blk (UniProt-ID: P51451). According to Orphanet,
Blk is linked to maturity-onset diabetes of the young (MODY,
Published in partnership with the Systems Biology Institute

Fig. 6 Correlation between interaction energies calculated for
DrugBank and Orphanet complex models. Each gray dot represents
a drug-target pair from the DrugBank database, whose DFIRE score
is displayed on the x-axis. Since a drug can be repositioned to
multiple Orphanet proteins, the mean DFIRE score ± standard error
is displayed on the y-axis. Linear regression is shown as a solid line

ORPHA:552, GARD:3697)50 caused by mutations in at least 13
genes, 5 of which are placed within 100 kb corresponding to the
Blk gene.51 Nonetheless, a reassessment study showed that Blk
mutations, A71T in particular, unlikely cause highly penetrant
MODY and may weakly inﬂuence type 2 diabetes risk in the
context of obesity.52 More recently, it was discovered that
malignant T cells in the majority of patients with the cutaneous
T-cell lymphoma (CTCL) display the ectopic expression of Blk.53
Since Blk functions as an oncogene promoting the proliferation of
malignant T cells, it is a potential therapeutic target in CTCL.54
Although the full-length experimental structure of Blk is
unavailable, a conﬁdent model of Blk, whose estimated Global
Distance Test (GDT)-score55 (Supplementary Text S2) is 0.72, was
constructed by eThread based on proto-oncogene tyrosineprotein kinase Src (PDB-ID: 1y57, chain A, 64% sequence identity
npj Systems Biology and Applications (2018) 13
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Fig. 7 Example of a recently determined structure corroborating repositioning prediction by eMatchSite. Ibrutinib repositioned from tyrosineprotein kinase BTK to tyrosine-protein kinase Blk is compared to the X-ray structure of tyrosine-protein kinase HCK complexed with ligand
OOS. a Chemical structures of the repositioned drug, ibrutinib, and the co-crystallized ligand, OOS. b The modeled structure of the ibrutinibBlk complex, colored in purple, is globally superposed onto the experimental OOS-HCK structure, colored in gold. Proteins are shown as
ribbons, ligands as sticks, and binding residues predicted by eFindSite in Orphanet models as spheres. Non-carbon atoms in ligands are
colored by atom type (red–oxygen, blue–nitrogen, yellow–sulfur)

to Blk).56 Further, the binding site annotated in the Blk model by
eFindSite with a 99.2% conﬁdence (Supplementary Text S6) was
matched to the ibrutinib-binding pocket in tyrosine-protein kinase
BTK with a high eMS-score of 0.99. In October 2017, tyrosineprotein kinase HCK co-crystallized with a 7-substituted pyrrolopyrimidine inhibitor, OOS (PDB-ID: 5h0e, chain A), sharing 69.7%
sequence identity with Blk, was released in the PDB.57 Figure 7a
shows that ibrutinib and OOS have very similar chemical
structures with a Tanimoto coefﬁcient58 (TC, Supplementary Text
S7) of 0.61 and 27 common atoms.
The global superposition of the modeled ibrutinib-Blk and
experimental OOS-HCK structures is presented in Fig. 7b. The Blk
model (purple ribbons) has a globally correct structure with a TMscore of 0.86 and a Cα-RMSD of 2.25 Å calculated against HCK
(gold ribbons) over the kinase domain. Further, binding residues
were accurately predicted by eFindSite in the Blk model (purple
spheres) with a MCC of 0.60 against OOS-binding residues in the
HCK complex structure. Encouragingly, the binding pose of
ibrutinib repositioned to Blk based on the local BTK→Blk
alignment closely resembles the conformation of OOS in HCK.
The RMSD calculated over equivalent non-hydrogen atoms of
these compounds is 2.57 Å and 1.43 Å upon the superposition of
target proteins and ligands, respectively. Despite the fact that
matching binding sites in a sequence-order independent manner
is a challenging task, the modeled ibrutinib-Blk complex is
noticeably similar to the experimental OOS-HCK structure recently
released in the PDB.
Niemann-Pick disease, type C and exemestane
Niemann-Pick disease, type C (NPC, ORPHA:646) is a fatal
hereditary disorder characterized by the accumulation of lowdensity, lipoprotein-derived cholesterol in lysosomes causing
hepatosplenomegaly and severe progressive neurological dysfunction. Mutations in either of two lysosomal proteins, NiemannPick disease types C1 (NPC1) or C2 (NPC2), interrupt sterol
transport from late endosomes and lysosomes to other cellular
organelles resulting in cholesterol accumulation in lysosomes and
the fatal NPC disease.59 As many as 22 mutations in NPC2 are
associated with orphan NPC diseases, including adult, juvenile,
late infantile, and severe early infantile neurologic onset. In
npj Systems Biology and Applications (2018) 13

particular, V30M, V39M, C47F, S67P, C93F, C99R, and P120S
mutations in NPC2 have an effect on cholesterol binding.60–64
Furthermore, mutations of M79, V81, and V83 block sterol
transport making NPC2 a promising drug target to treat NPC
diseases.65 Interestingly, eMatchSite detected a signiﬁcant structure similarity between the cholesterol-binding pocket of NPC2
and the steroid-binding pocket of cytochrome P450 aromatase
(CYP19A1), an enzyme involved in the biosynthesis of aromatic
C18 estrogen from C19 androgen. CYP19A1 is a target for
exemestane, an oral steroidal aromatase inhibitor approved by
the FDA for the treatment of breast cancer in postmenopausal
patients.66
The full-length model of CYP19A1 was generated by eThread
from the crystal structure of an N-terminal-truncated recombinant
human CYP19A1 (PDB-ID: 4kq8, chain A, 100.0% sequence identity
with a coverage of 89.9%).67 Subsequently, exemestane was
placed in the steroid-binding pocket of CYP19A1 based on its
global structure alignment with the X-ray structure of human
placental CYP19A1 (PDB-ID: 3s79, chain A, TM-score of 0.89 and
Cα-RMSD 0.55 Å) bound to androstenedione,68 another steroidal
inhibitor with a TC to exemestane of 0.95. Although the
experimental structure of CYP19A1 bound to exemestane is
available (PDB-ID: 3s7s, chain A),68 it is not included in the
template library used to model DrugBank complexes. By reason of
removing the redundancy in the library at 80% protein sequence
identity33 and a TC of 0.9 for the ligand chemical similarity,34
androstenedione-bound CYP19A1 was identiﬁed as a cluster
centroid to represent the entire group of similar complexes,
including the exemestane-CYP19A1 structure.
We selected this case to demonstrate that a non-redundant
library is adequate to build complex models fairly indistinguishable from experimental structures. The exemestane-CYP19A1
model constructed in this study is shown in Fig. 8a as thick sticks
colored by atom type representing exemestane and purple
ribbons representing CYP19A1. Two other structures are globally
aligned
onto
the
exemestane-CYP19A1
model,
the
androstenedione-CYP19A1 complex used as the template to
position exemestane within the steroid-binding pocket and the
experimentally determined exemestane-CYP19A1 complex; both
structures are presented in Fig. 8a as thin sticks colored by atom
Published in partnership with the Systems Biology Institute
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Fig. 8 Repositioning of exemestane from cytochrome P450 aromatase (CYP19A1) to Niemann-Pick disease type C2 protein (NPC2). CYP19A1
and NPC2 proteins are colored in purple and gold, respectively, whereas ligands are colored by atom type (green/teal–carbon, red–oxygen,
yellow–sulfur). a Global superposition of the modeled complex between CYP19A1 (purple ribbons) and exemestane (thick sticks), and two
experimental structures of CYP19A1 (teal ribbons) bound to androstenedione and exemestane (thin sticks). Binding residues are shown as
spheres. b Global superposition of the NPC2 model (gold ribbons) and two experimental structures of NPC2, human and bovine (teal ribbons),
bound to cholesterol sulfate (thin sticks). Binding residues are shown as spheres. In addition, the steroid-binding pocket predicted by
eFindSite is represented by a cluster of template-bound ligands (transparent sticks) extracted from the following template proteins
superposed onto the NPC2 model (template-proteins are not shown): GM2A (PDB-IDs: 2ag2, 1tjj, 2agc), LY96 (PDB-IDs: 2e59, 2e56, 4g8a, 3fxi,
2z65, 3mu3, 3rg1, 5ijd, 3vq2, 3m7o), DERF2 (PDB-ID: 1xwv), and NPC2 (PDB-IDs: 5kwy,2hka, 3web). c Cross section of the internal cavity in the
NPC2 structure exposing the repositioned exemestane (thick sticks). CYP19A1 (purple ribbons) and NPC2 (gold surface) are locally superposed
according to the sequence order-independent pocket alignment by eMatchSite. Annotated binding residues in NPC2 are solid, whereas the
remaining surface is transparent

type and teal ribbons. Indeed, the Cα-RMSD, as well as the RMSD
calculated over binding residues between CYP19A1 model and
experimental structure are below 1 Å. Further, RMSD calculated for
exemestane upon the global structure superposition is as low as
0.06 Å demonstrating that the exemestane-CYP19A1 assembly is
modeled with a very high accuracy. It is also noteworthy that
eFindSite identiﬁed the binding site for exemestane with 96.2%
conﬁdence and the predicted binding residues, shown as purple
spheres in Fig. 8a, yield an MCC of 0.71 against exemestanebinding residues in the CYP19A1 model.
The full-length model of lysosomal protein NPC2 was constructed based on the crystal structure of the human NPC2 (PDBID: 5kwy, chain C, 100.0% sequence identity with a coverage of
87.4%).65 Figure 8b shows the global superposition of the NPC2
model represented by gold ribbons and two experimental
NPC2 structures represented by teal ribbons, human (the
template, 5kwyC) and bovine (PDB-ID: 2hka, chain A, 79%
sequence identity to human NPC2),69 both complexed with
cholesterol sulfate. These superpositions yield a Cα-RMSD of
0.92 Å against human and 1.06 Å against bovine structures. NPC2
has an Ig-like β-sandwich fold comprising seven β-strands forming
a hydrophobic pocket that was suggested to become wider in
order to accommodate cholesterol-like molecules.70 This region
was accurately identiﬁed by eFindSite with a high conﬁdence of
95.2% as a highly hydrophobic binding site formed by 20
conserved residues. The prediction was made based on a nonredundant set of 21 holo-templates, including ganglioside GM2
activator (GM2A), lymphocyte antigen 96 (LY96), mite group 2
allergen Der f 2 (DERF2), and NPC2 itself. Selected template-bound
ligands are shown in Fig. 8b as a cluster of transparent, teal
molecules upon the global alignment of template proteins onto
the NPC2 model. In addition, eFindSite estimated that the average
± standard deviation molecular weight (MW), octanol-water
partition coefﬁcient (logP), and polar surface area (PSA) for
molecules binding to this region on the NPC2 surface are 383 Da
± 225, 4.76 ± 1.97, and 90.2 Å2 ± 77.9, respectively. The predicted
physicochemical properties of putative binders of NPC2 are a
good match for exemestane (and androstenedione), whose MW is
296 Da (286 Da), logP is 4.03 (4.09), and PSA is 34.1 Å2 (34.1 Å2).
Although the global similarity between CYP19A1 and NPC2 is
low as assessed by a TM-score of 0.14 and 5.2% sequence identity,
eMatchSite predicted that their binding sites are in fact similar
Published in partnership with the Systems Biology Institute

with a high eMS-score of 0.86. Figure 8c shows exemestane
repositioned from CYP19A1 to the cholesterol-binding pocket of
NPC2 based on the sequence order-independent local alignment
reported by eMatchSite. Exemestane ﬁts into a deep, non-polar
cavity in the NPC2 structure forming a number of hydrophobic
interactions with Y55, V57, V73, V74, F85, P88, Y109, N111, L113,
V126, W128, and W141. Encouragingly, an interaction energy of
−409.5 calculated with DFIRE for the exemestane-NPC2 complex
is lower than a value of −381.4 for exemestane-CYP19A1
indicating that this drug may form favorable interactions with
NPC2. Notably, exemestane adopts a conformation distinct from
that of cholesterol sulfate in the crystal structure of NPC2. The
latter is larger (MW of 466 Da) and has two moieties attached to
the steroid scaffold, an aliphatic branched-chain interacting with
the inner part of the NPC2 pocket and a polar sulfate group
protruding from the pocket toward the cholesterol-transfer tunnel
between NPC2 and the N-terminal domain of NPC1.65 In contrast,
smaller exemestane may bind deeper in the NPC2 structure to
inhibit conformational changes required for transporting cholesterol to NPC1.
This conjecture is supported by several recent studies. For
instance, U18666A, a cationic sterol similar to exemestane with a
TC of 0.67, binds to NPC1, inhibiting cholesterol export.71 Further,
FDA-approved ezetimibe was shown to target NPC1 decreasing
the cholesterol level.72 Another study independently suggests
repurposing thiabendazole, a potent inhibitor of cytochrome P450
1A2 (CYP1A2), to NPC1.73 Note that CYP1A2 and CYP19A1 are
members of the cytochrome P450 family74 (Pfam-ID: PF00067) and
have highly similar structures with a TM-score of 0.87. Finally,
NPC2 was demonstrated to bind a range of cholesterol-related
molecules, leading to an alteration of its function in lysosomal
cholesterol transport.75 On that account, we hypothesize that
exemestane binding to NPC2 disrupts the dynamics of its
hydrophobic cavity. This effect could be exploited as a viable
strategy to impede sterol movement to NPC1 preventing the
accumulation of cholesterol in lysosomes in NPC disease.
CONCLUSIONS
Rational repositioning of existing drugs is expected to play a major
role in the development of treatments for orphan diseases.
Comparing ligand-binding sites in protein structures is among the
npj Systems Biology and Applications (2018) 13
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most promising computational techniques to inform drug
repurposing efforts. In this study, we demonstrate that combining
eMatchSite with structure-based virtual screening enhances the
accuracy of the detection of similar binding pockets. This
promising methodology was employed to match drug-binding
pockets from DrugBank with those from Orphanet exposing a
number of opportunities to combat orphan diseases with existing
drugs.

Data availability
Data generated for the repositioning of DrugBank drugs to Orphanet
proteins are available from the Open Science Framework at https://osf.io/
qdjup/. The source codes of programs used in this study are available from
GitHub, eThread: https://github.com/michal-brylinski/ethread, eFindSite:
https://github.com/michal-brylinski/eﬁndsite, and eMatchSite: https://
github.com/michal-brylinski/ematchsite.
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a template-based structure prediction algorithm.33 In the next step, drugbinding pockets were predicted by eFindSite34 in conﬁdently modeled
target DrugBank and Orphanet proteins whose estimated GDT-score is
≥0.4. Drug repositioning utilizes only those binding sites assigned a high
and moderate conﬁdence. Further, we devised a two-step alignment
protocol to position drug compounds within the predicted binding
pockets in the DrugBank proteins. First, holo-templates selected by
eFindSite were structurally aligned onto the target protein with Fr-TMalign35 and then the drug molecule was superposed onto the most similar
template-bound ligand according to the chemical alignment constructed
by KCOMBU.36 The Orphanet dataset comprises 922 proteins, whereas the
DrugBank dataset contains 2012 drug-protein complexes formed by 715
drugs and 348 proteins.

Matching DrugBank and Orphanet pockets
All-against-all matching of drug-binding pockets in DrugBank and
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physicochemical features and evolutionary proﬁles. For signiﬁcant matches
identiﬁed with eMatchSite, drugs bound to the DrugBank target were
transferred to a binding site in the Orphanet protein upon the
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models is assessed by a knowledge-based statistical energy function for
protein-ligand complexes with DFIRE38 and VS with Vina.17

Huang dataset
The Huang dataset was originally compiled to evaluate the performance of
geometry-based methods to predict binding pockets21 and then it was
adopted to assess the accuracy of pocket comparison algorithms.78 From
this dataset, we selected 107 proteins for which eFindSite correctly
annotated binding sites within a distance of 8 Å from the geometric center
of the bound ligand in the experimental complex structure. These target
proteins bind the following ligands, adenosine, biotin, fructose-6phosphate, α-L-fucose, β-D-galactose, guanine, α-D-mannose, O1-methylmannose, 4-phenyl-1H-imidazole, palmitic acid, retinol, and 2’-deoxyuridine 5’-monophosphate. The comprehensive information on the Huang
dataset is given in Supplementary Table S1.
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non-redundant library of 1515 FDA-approved drugs compiled previously.20
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partial charges, as well as to convert target proteins and library
compounds to the PDBQT format. For each docking ligand, the optimal
search space centered on the binding site annotated with eFindSite was
calculated from its radius of gyration.81 Molecular docking was carried out
with AutoDock Vina 1.1.2 and the default set of parameters.
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